IAS 2025

IAS 2025, the 13th International AIDS Society Conference on HIV Science, highlights important advances in HIV research, their applications in policy and practice, and current issues impacting HIV prevention and treatment worldwide.

Day 1

US Funding Cuts Threaten Community HIV Response in Latin America and...

July 14, 2025

US Funding Impedes HIV Services in Mozambique

July 14, 2025

PEPFAR Funding Cuts Restrict HIV PrEP Access in Sub-Saharan Africa

July 14, 2025

UNAIDS Report: Moving Forward Despite the 2025 Funding Crisis

July 14, 2025

Day 2

Cabotegravir and Lenacapavir Are Highly Effective in Preventing HIV

July 16, 2025

Safety and Efficacy of Lenacapavir for Pregnant and Lactating People

July 16, 2025

Long-Acting Lenacapavir Is Needed to Protect Girls and Young Women Against...

July 16, 2025

PILLAR Study: One Year Data Shows High Satisfaction With Cabotegravir

July 16, 2025

Day 3

African American Cisgender Women’s Barriers to PrEP and Strategies to Overcome...

July 17, 2025

New HIV Diagnoses in US Associated With Systemic Racism

July 17, 2025

Precision-Guided, Region-Specific Tools to Help Reach Global HIV Goals

July 17, 2025

Cabotegravir Long-Lasting Injectable Benefits US Black Women

July 17, 2025

Day 4

PrEP Services Through Pharmacies Fill Large Treatment Gap in Malaysia

July 21, 2025

Pharmacies Offer New PrEP Delivery Platform in Kenya

July 21, 2025

Community Pharmacies in Uganda Connect Young Women to HIV Preventive Care

July 21, 2025

IAS 2025

Day 1

Day 2

Day 3

Day 4

Quick Links